Dermira Inc. (DERM) VP Christopher M. Griffith Sells 1,303 Shares

Dermira Inc. (NASDAQ:DERM) VP Christopher M. Griffith sold 1,303 shares of the stock in a transaction dated Monday, October 17th. The stock was sold at an average price of $32.33, for a total value of $42,125.99. Following the transaction, the vice president now directly owns 45,165 shares in the company, valued at approximately $1,460,184.45. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of Dermira Inc. (NASDAQ:DERM) opened at 32.99 on Wednesday. Dermira Inc. has a 12 month low of $17.42 and a 12 month high of $36.16. The stock’s 50 day moving average price is $33.56 and its 200 day moving average price is $30.32. The firm’s market cap is $1.17 billion.

Dermira (NASDAQ:DERM) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.03. Equities research analysts predict that Dermira Inc. will post ($3.46) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

A number of equities research analysts have issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 price target on shares of Dermira in a research report on Wednesday, September 21st. Leerink Swann reaffirmed a “buy” rating on shares of Dermira in a research report on Wednesday, October 5th. Finally, Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a research report on Tuesday, August 2nd. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $41.00.

A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in Dermira by 1.0% in the first quarter. BlackRock Inc. now owns 49,260 shares of the biopharmaceutical company’s stock valued at $1,018,000 after buying an additional 499 shares during the period. ProShare Advisors LLC boosted its stake in Dermira by 3.6% in the second quarter. ProShare Advisors LLC now owns 24,914 shares of the biopharmaceutical company’s stock valued at $729,000 after buying an additional 869 shares during the period. BlackRock Group LTD boosted its stake in Dermira by 1.0% in the first quarter. BlackRock Group LTD now owns 197,240 shares of the biopharmaceutical company’s stock valued at $4,079,000 after buying an additional 1,898 shares during the period. Teachers Advisors Inc. boosted its stake in Dermira by 1.9% in the first quarter. Teachers Advisors Inc. now owns 123,531 shares of the biopharmaceutical company’s stock valued at $2,555,000 after buying an additional 2,278 shares during the period. Finally, American International Group Inc. boosted its stake in Dermira by 28.7% in the second quarter. American International Group Inc. now owns 12,085 shares of the biopharmaceutical company’s stock valued at $353,000 after buying an additional 2,695 shares during the period. Institutional investors own 82.57% of the company’s stock.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

5 Day Chart for NASDAQ:DERM

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
GoPro Planning to Cut 200 Jobs
GoPro Planning to Cut 200 Jobs
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Retailers Anticipating Strong Support for Small Business Saturday
Retailers Anticipating Strong Support for Small Business Saturday
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Eli Lilly Alzheimer’s Drug Does Not Pass the Test


 
© 2006-2016 Ticker Report. Google+.